Markets:

Overview

News

Currencies

International

Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

54.71 -1.67 (-2.96%)

Streaming Delayed Price Updated: 10:17 AM EDT, May 29, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2

...

18 19 20 21 22 23 24 25 26

...

36 37 Next >

2 Under-the-Radar Biotech Stocks to Buy in 2023 ↗

June 28, 2023

These companies are coming into their own.

Via The Motley Fool

The Best Stocks to Invest $20,000 in Right Now ↗

June 28, 2023

You can invest in these companies with $20,000 -- or even a lot less.

Via The Motley Fool

Why Shares of Nkarta Are Slumping Tuesday ↗

June 27, 2023

The pharmaceutical stock dropped after announcing so-so clinical trial results.

Via The Motley Fool

Wall Street Estimates That CRISPR Therapeutics Stock Could Jump 49%. Here's Why That's Right. ↗

June 27, 2023

With two huge catalysts drawing near, its stock could go even higher.

Via The Motley Fool

What Is CRISPR And Why Should Your Portfolio Care? ↗

June 25, 2023

CRISPR Therapeutics continues to be at the forefront of CRISPR-based therapeutics development. It's the first, and largest, but not the only player.

Via Talk Markets

3 Monster Stocks in the Making to Buy Right Now ↗

June 25, 2023

They're not monsters now -- but just give them some time.

Via The Motley Fool

Is CRISPR Therapeutics Stock a Buy Now? ↗

June 21, 2023

CRISPR stock has climbed more than 40% so far this year.

Via The Motley Fool

Where Will CRISPR Therapeutics Be in 10 Years? ↗

June 14, 2023

The biotech is part of a revolution in gene-editing therapies.

Via The Motley Fool

What 17 Analyst Ratings Have To Say About CRISPR Therapeutics ↗

June 09, 2023

Via Benzinga

Alleged Industrial Espionage Makes an Interesting Story ↗

June 21, 2023

We also chat about Vertex Pharmaceuticals and its role at the center of cystic fibrosis treatment.

Via The Motley Fool

Cathie Wood Is Buying This Growth Stock and Selling Its Competitor. Should You Follow Suit? ↗

June 21, 2023

There's more than one reason to sell a stock while buying another.

Via The Motley Fool

Buying This Growth Stock Hand-Over-Fist Right Now Could Make You a Lot Wealthier by 2030 ↗

June 21, 2023

This company has several catalysts for growth coming up, with more on the way.

Via The Motley Fool

3 Millionaire-Maker Biotech Stocks to Buy and Hold Forever ↗

June 20, 2023

Here are three long-term biotech stock investments that have the opportunity to turn risk -tolerant investors into millionaires.

Via InvestorPlace

Here's the Secret Behind Cathie Wood's Latest Moneymaking Strategy ↗

June 18, 2023

Success could be in the DNA of the Ark Invest founder.

Via The Motley Fool

How Biotech Stocks Are Revolutionizing Healthcare Investment Opportunities ↗

June 17, 2023

The field of biotechnology has become a driving force behind groundbreaking medical advancements, offering investors the opportunity to benefit from these innovations. Here are 10 healthcare innovators...

Via Talk Markets

3 Cathie Wood Investments That Could Deliver Superior Returns ↗

June 17, 2023

These three stocks fit Wood's profile for big-time growth.

Via The Motley Fool

2 Short-Squeeze Candidates That Could Go Parabolic ↗

June 15, 2023

Editas Medicine and Bluebird Bio have been favorite targets for short-sellers lately.

Via The Motley Fool

This Move Is a First for the FDA. Could It Signal a Big Turning Point for CRISPR Therapeutics? ↗

June 13, 2023

All eyes are on CRISPR Therapeutics' gene editing technology.

Via The Motley Fool

5 Stocks to Buy With Explosive 500% Potential ↗

June 12, 2023

Take advantage of a bullish change in investor sentiment with these five stocks to buy for 500% upside potential.

Via InvestorPlace

2 Biotech Stocks That Could Help Make You a Fortune ↗

June 12, 2023

Biotech stocks with cutting-edge therapies have the potential to generate substantial returns over time.

Via The Motley Fool

3 No-Brainer Stocks to Buy in June ↗

June 10, 2023

These biopharma stocks could be big winners.

Via The Motley Fool

Breakthrough in CRISPR-Based Therapy: FDA Accepts Vertex and CRISPR Therapeutics' Exa-cel Application ↗

June 09, 2023

The FDA has accepted the application for Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics AG (NASDAQ: CRSP) exa-cel for sickle cell disease and transfusion-dependent

Via Benzinga

Vertex/CRISPR Partnered Cell Therapy Shows Encouraging In Sickle Cell Disease, Thalassemia Patients ↗

June 09, 2023

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and CRISPR Therapeutics AG (NASDAQ: CRSP) announced that pivotal trials for exagamglogene autotemcel (exa-cel) for transfusion-dependent...

Via Benzinga

Carvana (CVNA) Stock Continues to Move on Improved Outlook ↗

June 09, 2023

Carvana (CVNA) stock is still a hot topic among traders on Friday after the used-car retailer updated its outlook yesterday.

Via InvestorPlace

TGT Stock Alert: Have Target’s Sales Numbers Peaked? ↗

June 09, 2023

Target (TGT) stock is in hot water on Friday after Citi analyst Paul Lejuez warned investors to stay away from the retailer.

Via InvestorPlace

Why Is CRISPR Therapeutics (CRSP) Stock Moving Today? ↗

June 09, 2023

CRISPR Therapeutics (CRSP) stock is on the move Friday after the company revealed data from its CLIMB-111 and CLIMB-121 clinical trials.

Via InvestorPlace

Crispr Stock Slips; The FDA Could Approve The First CRISPR-Based Gene-Editing Drug In Just Six Months ↗

June 09, 2023

The agency said it will make an approval decision on Crispr's exa-cel in December.

Via Investor's Business Daily

Wall Street Loves These 3 Growth Stocks -- Should You? ↗

June 09, 2023

Analysts think all three of these stocks could soar.

Via The Motley Fool

Positive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Presented at the 2023 Annual European Hematology Association (EHA) Congress

June 09, 2023

From Vertex Pharmaceuticals Incorporated

Via Business Wire

FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

June 08, 2023

From Vertex Pharmaceuticals Incorporated

Via Business Wire

< Previous 1 2

...

18 19 20 21 22 23 24 25 26

...

36 37 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.